SG Americas Securities Trims Sarepta Therapeutics Stake

Institutional investor reduces position in biotech company by over 60%

Apr. 3, 2026 at 9:06am

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy industrial banking equipment, conveying the tangible, physical nature of institutional investment decisions.A reduction in institutional ownership of Sarepta Therapeutics shares highlights the complex financial forces shaping the biotech industry.Cambridge Today

SG Americas Securities LLC has reduced its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 62.8% during the fourth quarter, according to a recent 13F filing. The fund now owns 191,371 shares of the biotechnology company's stock, down from 514,151 shares previously.

Why it matters

Sarepta Therapeutics is a leading developer of precision genetic medicines for rare neuromuscular diseases. Changes in institutional ownership can signal shifts in investor sentiment and influence the company's stock price performance.

The details

According to the 13F filing, SG Americas Securities sold 322,780 shares of Sarepta Therapeutics during the fourth quarter. The fund now owns approximately 0.18% of the company's outstanding shares, valued at $4.1 million as of the end of the reporting period.

  • SG Americas Securities filed the 13F report on April 3, 2026, disclosing its Q4 2025 holdings.
  • The fund reduced its Sarepta Therapeutics position during the fourth quarter of 2025.

The players

SG Americas Securities LLC

An institutional investment firm that has reduced its stake in Sarepta Therapeutics.

Sarepta Therapeutics, Inc.

A biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in SG Americas Securities' Sarepta Therapeutics holdings could signal a shift in investor sentiment towards the biotech company, though further analysis would be needed to determine the broader implications for the stock.